Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Frontiers in MedicineOpen Access

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJiaying ChengHFHaipeng FuLJLing Jiang

Discussion

Loading...

Member takes

Overview

Retrospective study shows venetoclax plus HMAs improves overall survival and remission in AML patients, indicating a safer treatment option.

Key Points

  • The venetoclax-based regimen achieved a 56.6% complete remission rate, compared to 26.4% with chemotherapy.
  • Overall survival was significantly higher with venetoclax plus HMAs, with a median of 12.6 months versus 5.8 months.
  • The study included 106 patients treated between 2020 and 2024, assessing various outcome measures.
  • Findings suggest venetoclax therapy may lower risks of severe cytopenias and infections in this patient group.

Cite This Study

Cheng et al. (2025) studied this question.

synapsesocial.com/papers/68d42328713b0b5dfea6afbbhttps://doi.org/10.3389/fmed.2025.1638176
View Full Paper
Ask AI
Bookmark
Share